Sprott Inc. Biogen Inc. Transaction History

Sprott Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$223.92 - $287.77 $5.6 Million - $7.19 Million	-25,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$259.0 - $414.71 $3.89 Million - $6.22 Million	-15,000 Reduced 37.5%	25,000 $8.66 Million
Q4 2020 Feb 16, 2021	BUY	$236.26 - $355.63 $1.89 Million - $2.85 Million	8,000 Added 25.0%	40,000 $9.79 Million
Q2 2020 Aug 14, 2020	BUY	$258.66 - $342.55 $517,320 - $685,100	2,000 Added 6.67%	32,000 $8.56 Million
Q1 2020 May 15, 2020	BUY	$268.85 - $341.04 $8.07 Million - $10.2 Million	30,000 New	30,000 $9.49 Million
Q4 2019 Feb 13, 2020	SELL	$220.06 - $304.07 $7.7 Million - $10.6 Million	-35,000 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$217.44 - $243.88 $3.26 Million - $3.66 Million	15,000 Added 75.0%	35,000 $8.15 Million
Q2 2019 Aug 14, 2019	BUY	$219.29 - $241.72 $1.1 Million - $1.21 Million	5,000 Added 33.33%	20,000 $4.68 Million
Q1 2019 May 15, 2019	BUY	$216.71 - $338.96 $3.25 Million - $5.08 Million	15,000 New	15,000 $3.55 Million

1,006

126M

1.77M

2.34M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $20.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Sprott Inc., based on Form 13F filings with the SEC.

Stay updated on Sprott Inc. with notifications on news.